21健讯Daily｜小儿感冒宁颗粒和蒲公英颗粒转为非处方药；派格生物港交所上市；漱玉平民股东拟减持

Policy Developments - The National Medical Products Administration (NMPA) announced the conversion of Xiaoer Ganmao Ning Granules and Pugongying Granules from prescription to over-the-counter drugs [1] Drug Approvals - Eisai's lemborexant has been approved by the NMPA for sale in China, targeting adult insomnia, particularly difficulties in falling and maintaining sleep [2] - Rongchang Biologics' injectable Taitasip has received NMPA approval for a new indication to treat generalized myasthenia gravis (gMG) [3] Capital Markets - Chenglian Technology has successfully completed nearly 200 million RMB in B+ round financing, bringing its total financing to over 500 million RMB [4] - Xiantong Pharmaceutical has submitted a listing application to the Hong Kong Stock Exchange, with CICC and CITIC Securities as joint sponsors [5] Industry Collaborations - Drug Ranch has reached an option agreement with Xiamen Tebao Biotech for clinical collaboration on the ALPK1 agonist DF-006 for hepatitis B and liver cancer in Greater China [6] - Chengdu Guowei Biopharmaceutical has signed a new drug research cooperation agreement with Xinlitai, granting exclusive rights for the AGT-siRNA drug GW906 in the Chinese market [8] Market Activity - Paige Biotech has officially listed on the Hong Kong Stock Exchange with an issue price of 15.6 HKD per share, corresponding to a market capitalization of approximately 6.02 billion HKD [7] - The innovative drug sector is experiencing increased activity, with companies actively pursuing technology or commercial rights to accelerate resource integration [9] Corporate Changes - Taiji Group announced the resignation of supervisor Xu Tingmei due to work reasons, which will not affect the normal operation of the supervisory board [10] - Shareholder Qin Guangxia of Shuyuping plans to reduce her stake by up to 3%, amounting to a maximum of 12.07 million shares [11] - Seer Medical announced the transfer of 51% equity in its subsidiary Akesu Yonglin, with part of the transfer payment of 4.2 million RMB still outstanding [12]